The thymidine analogue 3 -deoxy-3 -[
Introduction
Tumor cell proliferation is a useful prognostic indicator of tumor aggressiveness, and proliferation may be evaluated to monitor and predict the response to antitumor therapy. Tumor cells and tissues with a high proliferation rate require a high rate of DNA synthesis [1] [2] [3] [4] [5] . Radiolabeled thymidine analogues are standard biomarkers for DNA synthesis and are generally used in nuclear medicine. One thymidine analogue, [ 11 C]-labeled thymidine, is well known as a radiotracer for positron emission tomography (PET) studies of tumor cell proliferation and DNA synthesis [6] [7] [8] [9] . However, the short physical half-life (20 min) of [ 11 C]-thymidine and its rapid biodegradation are practical limitations to its use [4, 10] . Consequently, the use of [ 18 F]-labeled 3 -deoxy-3 -fluorothymidine ([ 18 F]FLT) PET imaging to assess proliferation in various tumors has been reported in preclinical and clinical studies [11] [12] [13] [19, 20] .
In this study, we monitored TK1 activity by quantifying FLT and FLT-MP in vivo using 19 
Results and Discussion
To detect the locations of FLT and FLT-MP, we investigated the 19 19 F MRS of the mixture; here, the former was FLT-MP and the latter was FLT. Because the area ratios of the spectra for the former and latter were approximately 60 and 100, respectively, the findings were consistent with the concentrations in the mixture of FLT-MP (60 mM) and FLT (100 mM).
We investigated whether the 19 F NMR or 19 F MRS signal of intracellular FLT-MP, produced as an FLT metabolite, could be detected in vitro. In the first group of cells that were not washed, both FLT and FLT-MP were clearly observed in the 19 F NMR spectra, although the FLT-MP peak was very weak ( Figure S3 ). However, the signal for FLT in the cells was very strong, and the concentration of FLT was 16.7 mM. In contrast, an FLT-MP peak in the first group of cells was not observed in the 19 F MRS; only an FLT peak was observed ( Figure S4 ). Figure 3 shows the 19 F NMR spectra of washed cells in the second group as a function of time. Both intracellular FLT and FLT-MP were clearly observed at −175.2 ppm and −174.5 ppm, respectively. Because the extra FLT was washed out, the FLT signal exhibited a moderate level relative to the cells in the first group. Although the extra FLT was washed out, the presence of FLT demonstrated that FLT and its metabolites were reversible in the cell [2] . The amounts of intracellular FLT-MP and FLT were therefore inconsistent over time. A relative ratio of FLT to FLT-MP, here, demonstrated the on-going phosphorylation of different spectra in various tumors unlike PET technology.
No peak was observed in the 19 F MRS signal for intracellular FLT-MP formed in the second group of cells because of its low concentration. These results demonstrated that a typical FLT concentration of 16.7 mM is required for in vivo detection by 19 F MRS. As previous reports, in vivo 19 F MR imaging is generally used for the high concentration of 89 mM due to the low sensitivity of that [21] .
To chemically confirm the accuracy of quantitation and metabolite detection by 19 F MRS, an HPLC assay was performed. (Figure 4(c) ).
We, then, investigated the in vivo 19 F MR signals for FLT and FLT-MP. More precisely, we aimed to observe that the appearance of the FLT-MP signal is caused by metabolism of FLT in vivo. [12] . PET technology, high sensitivity, and the radiation of positron-emitting radioisotopes can easily permeate tissues, making PET a powerful molecular imaging modality to monitor the progression of cancer [22] . However,
PET alone cannot readily distinguish between [
18 F]FLT and
Specifically, it is very difficult to simultaneously identify metabolites in vivo by kinetic analysis of FLT-PET images [8] . In that respect, our results show that 19 F MRS is a noninvasive and practical way to identify biomolecules in vivo, including fluorine atoms; it may, thus, be utilized to complement other imaging tools, such as PET.
MRI/MRS is also a promising molecular imaging method for cancer theragnostics [23, 24] . For example, 13 C MRI/MRS study of hyperpolarized [ 13 C]pyruvate and its metabolite ([ 13 C]lactate) could be recently used to measure early responses to therapy, and the utilization of metabolite levels has been studied in clinical practice [25] [26] [27] . The hyperpolarized 13 C compounds, however, have restriction on the metabolism studies of DNA synthesis due to a time limit of hyperpolarization. The results of the present study, though 
Conclusion
In this study, FLT and its metabolite were measured for the first time in an in vivo mouse model using 19 
Materials and Methods

Chemicals.
All reagents were purchased from commercial sources, and the following agents were FLT and FLT-MP (Research Center FutureChem Co., Ltd., Seoul, Korea) and trifluoroacetic acid (TFA) (Sigma-Aldrich, St. Louis, MO).
High-Performance Liquid Chromatography (HPLC).
The locations of compound were confirmed by analytical HPLC using an Atlantis C 18 analytical column (5 m, 3.0 × 150 mm) with 10% EtOH in water (v/v) as the mobile phase at a flow rate of 0.4 mL/min. The retention times ( ) for FLT and FLT-MP were 7.1 min and 2 min, respectively.
Cell Culture.
The MCF-7 human breast cancer cell line expressing the HSV-tk gene was maintained in RPMI-1640 medium supplemented with 10% FBS, 1% antibiotics, and 100 g/mL of G418 (Invitrogen). Cultures were maintained in a 37 ∘ C incubator with 5% CO 2 , and the medium was changed every 3 days. For HPLC, the pellets were resuspended in PBS to a final volume of 1 mL and were then lysed by three cycles of freezing and thawing; the lysates were centrifuged at 14,000 rpm for 5 min at 4 ∘ C. The supernatant was used for HPLC analysis. FLT and FLT-MP were extracted from the samples after growth for 5 min, 30 min, 60 min, or 120 min by three cycles of freezing and thawing. After centrifugation (14,000 rpm for 5 min at 4 ∘ C), the samples comprising a 90 : 10 mixture of supernatant: D 2 O, were placed in 5 mm nuclear magnetic resonance (NMR) tubes for data acquisition.
NMR. The
19 F NMR measurements were conducted at 28 ∘ C on a Bruker 400-MHz NMR spectrometer, equipped with a 5-mm BBFO probe. The experimental parameters were as follows: pulse angle, 90 ∘ (18.32 sec); repetition rate, 1 sec; 172 K data set; 2,000 scans. All 19 F data were processed using TopSpin and analyzed with MestReNova. 
MRI. All
1 H MRI and 19 F MRI/MRS data were acquired with a 9.4T animal MRI system and 20 mm surface coil (370-420 MHz) (Agilent Technologies, USA).
1 H MR images were acquired with a fast spin echo sequence using the following settings: repetition time (TR) 2500 ms, echo time (TE) 25 ms, matrix 256 × 256, field of view (FOV) 5 × 5 cm 2 , slice thickness 2 mm, gap 0 mm, averages 2, and scan time 2 min 45 sec.
19 F MR images of phantom were acquired with a gradient echo sequence using the following settings: TR 100 ms, TE 4.0 ms, matrix 64 × 64, FOV 5 × 5 cm 2 , slice thickness 2 mm, gap 0 mm, averages 1200, and scan time 2 h 8 min.
19 F MRS of phantoms and in vivo data were acquired with Point-REsolved Spectroscopy (PRESS) using the following settings: TR 3000 ms, TE 15 ms, voxel size 5 × 5 × 5 mm 3 , averages 512, and scan time 25 min. 19 F MRS data were acquired with Point-REsolved Spectroscopy (PRESS) using TR 3000 ms, TE 15 ms, averages 512, scan time 25 min.
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